Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advanced Life Sciences’ pneumonia drug meets trial end point
The primary efficacy endpoint of statistical non-inferiority in the clinical cure rate at the test of cure visit was achieved. The study results showed that cethromycin cured 94%
The primary efficacy endpoint of statistical non-inferiority in the clinical cure rate at the test of cure visit was achieved. The study results showed that cethromycin cured 94%
The primary objective of the study is to determine the rate of durable complete response for tamibarotene therapy when administered as a single agent to adult patients with
At study end, pramlintide/metreleptin treatment reduced body weight on average by 12.7%, significantly more than treatment with pramlintide alone (8.4%). Subjects treated with pramlintide/metreleptin lost an average of
The new dressings, both in adhesive and non-adhesive versions, have been shown to lower the pH level of wounds. When wound pH is lowered, it has been shown
The initial clinical trial was a Phase I study of escalating single doses of the drug, G4544, in 30 normal volunteers. The endpoints of the study were to
The Phase I study will be an open label, multi-center dose escalation trial evaluating the safety and maximum tolerated dose of single or multiple dose administration of allogeneic
The program includes the COGENT-1 and COGENT-2 trials. COGENT (Clopidogrel and the optimization of gastrointestinal events trial) trials are designed to measure the incidence of upper gastrointestinal bleeding
Abilify is used for the treatment of pediatric patients aged 10 to 17 years old and diagnosed with bipolar I disorder, manic or mixed episode with or without
The STAR (Special Team Amplification of Research) program is being launched for the first Phase of research and development with a $3 million grant from the Safeway Foundation,
Pathway Diagnostics has licensed the patent (with rights to sub-license) from Health Research Incorporated (HRI), for use in the fields of laboratory diagnosis and monitoring. The patent discloses